Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-21.76%
0%
-21.76%
6 Months
29.07%
0%
29.07%
1 Year
6.35%
0%
6.35%
2 Years
-23.9%
0%
-23.9%
3 Years
-75.42%
0%
-75.42%
4 Years
-89.17%
0%
-89.17%
5 Years
-93.09%
0%
-93.09%
Nicox SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-9.00%
EBIT Growth (5y)
-31.97%
EBIT to Interest (avg)
-14.81
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.35
Sales to Capital Employed (avg)
0.58
Tax Ratio
1.17%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
7.20
EV to EBIT
NA
EV to EBITDA
EV to Capital Employed
3.64
EV to Sales
5.16
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
ROE (Latest)
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
7.90
6.90
14.49%
Operating Profit (PBDIT) excl Other Income
-37.00
-20.30
-82.27%
Interest
1.60
1.60
Exceptional Items
-0.70
0.00
Consolidate Net Profit
-22.40
-20.90
-7.18%
Operating Profit Margin (Excl OI)
-4,704.10%
-2,946.40%
-175.77%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 14.49% vs 32.69% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -7.18% vs 24.82% in Dec 2023
About Nicox SA 
Nicox SA
Pharmaceuticals & Biotechnology
Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The Company has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). It has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
Company Coordinates 
Company Details
Drakkar 2 - Batiment D, 2405 route des Dolines, CS 10313 Sophia Antipolis, VALBONNE None : 06560
Registrar Details






